Valuation: C4 Therapeutics, Inc.

Market Cap 471M 413M 381M 356M 668M 44.43B 682M 4.58B 1.77B 21.96B 1.77B 1.73B 76.15B P/E 2026 *
-4.56x
P/E 2027 * -4.23x
Enterprise Value 471M 413M 381M 356M 668M 44.43B 682M 4.58B 1.77B 21.96B 1.77B 1.73B 76.15B EV / Sales 2026 *
24.9x
EV / Sales 2027 * 24.6x
Free-Float
98.87%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: C4 Therapeutics, Inc.

1 day-3.18%
1 week+2.65%
Current month-2.52%
1 month+13.90%
3 months+76.76%
6 months+100.94%
Current year+123.04%
1 week 3.99
Extreme 3.99
4.58
1 month 3.44
Extreme 3.44
4.6
Current year 1.69
Extreme 1.6901
4.6
1 year 1.4
Extreme 1.395
4.6
3 years 1.06
Extreme 1.06
11.88
5 years 1.06
Extreme 1.06
51.21
10 years 1.06
Extreme 1.06
51.21
Manager TitleAgeSince
Chief Executive Officer 55 2020-10-01
Director of Finance/CFO 49 2023-09-17
Chief Tech/Sci/R&D Officer 56 2024-10-27
Director TitleAgeSince
Director/Board Member 74 2015-11-30
Director/Board Member 55 2020-09-13
Director/Board Member 55 2022-03-15
Date Insider Type Main position Quantity % Market Cap.
05-31Fiscal year

Founder

2,140 0.0019%
03-31Free

Director

5,370 0.0055%
03-31Free

Founder

4,259 0.0044%
Change 5-day change 1-year change 3-year change Capi.($)
-3.18%+2.65%+204.29%+54.91% 471M
-0.48%+7.20%-5.65%+3.69% 46.2B
+2.19%+11.71%+393.31%+609.31% 38.71B
+2.53%+13.93%+21.38%-10.96% 31.9B
+1.65%+3.61%+16.04%+55.24% 31.12B
-4.16%-2.58%+8.94%+26.14% 23.77B
-0.32%+12.96% - - 16.2B
+1.37%+14.53%+69.64%+136.34% 15.05B
+1.00%+10.30%+13.31%+23.36% 13.74B
+3.63%+9.53%+103.97%+106.25% 13.42B
Average +0.42%+8.23%+91.69%+111.59% 23.06B
Weighted average by Cap. +0.75%+8.32%+89.00%+137.94%

Financials

2026 *2027 *
Net sales 18.92M 16.59M 15.3M 14.32M 26.85M 1.79B 27.41M 184M 71.14M 882M 71.06M 69.51M 3.06B 19.14M 16.78M 15.47M 14.48M 27.16M 1.81B 27.72M 186M 71.94M 892M 71.87M 70.3M 3.09B
Net income -119M -104M -96.32M -90.18M -169M -11.24B -173M -1.16B -448M -5.56B -448M -438M -19.27B -151M -132M -122M -114M -214M -14.22B -218M -1.46B -567M -7.03B -566M -554M -24.37B
Net Debt - -
Logo C4 Therapeutics, Inc.
C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on delivering targeted protein degradation science to create a new generation of medicines that transform patients’ lives. The Company is focused on progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to design and optimize small-molecule medicines to address difficult-to-treat diseases. Its advanced product candidate, cemsidomide, is an orally bioavailable MonoDAC degrader of protein targets called IKZF1 and IKZF3. Cemsidomide is in clinical development for multiple myeloma (MM), and non-Hodgkin lymphoma (NHL). Its CFT1946 is an orally bioavailable BiDAC degrader designed to be potent and selective against BRAF V600X mutant proteins. It is also developing CFT8919, an orally bioavailable, allosteric, mutant-selective BiDAC degrader of epidermal growth factor receptor (EGFR), with an L858R mutation in non-small lung cancer (NSCLC).
Employees
104
Date Price Change Volume
26-06-26 US$4.260 -3.18% 20,144,416
26-06-25 US$4.400 +3.53% 2,595,150
26-06-24 US$4.250 +0.71% 2,735,773
26-06-23 US$4.220 +2.43% 2,912,409
26-06-22 US$4.120 -0.72% 2,995,936
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
4.260USD
Average target price
13.33USD
Spread / Average Target
+212.99%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CCCC Stock